Neurofibromatosis in Children: Actually and Perspectives.

Area of Science:

• Oncology
• Genetics
• Neurology

Background:

• Neurofibromatosis encompasses three types: NF1, NF2, and schwannomatosis, typically causing benign skin and nervous system tumors.
• Malignant neoplasms, particularly in NF1 patients, can exhibit aggressive behavior compared to the general population.
• Accurate differentiation of neurofibromatosis types is vital for diagnosis, management, and predicting tumor outcomes.

Purpose of the Study:

• To explore the link between neurofibromin deficiency and malignant tumor development in neurofibromatosis.
• To discuss the role of neurofibromin as a potential therapeutic target for managing neurofibromatosis-associated tumors.

Main Methods:

• Review of literature on neurofibromatosis types and associated neoplasms.
• Analysis of the function of neurofibromin in cellular proliferation and signaling pathways.
• Examination of current and developing therapeutic strategies for neurofibromatosis-related malignancies.

Main Results:

• Neurofibromin, a product of the NF1 gene, normally inhibits cell proliferation.
• Deficiency or dysfunction of neurofibromin is associated with an increased risk of aggressive malignant tumors in NF1.
• The precise mechanisms linking neurofibromin loss to specific malignant transformations require further elucidation.

Conclusions:

• Neurofibromin deficiency is a critical factor in the pathogenesis of aggressive tumors in neurofibromatosis type 1.
• Targeting neurofibromin pathways presents a promising avenue for future cancer therapies in affected individuals.
• Current therapeutic options for neurofibromatosis-associated malignancies are limited, with many treatments under investigation.